ReviewSignal transduction and targeted therapy2024
Exploring treatment options in cancer: Tumor treatment strategies.
Review in Signal transduction and targeted therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 512 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
512 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Exercise and pathologic complete response to cancer treatment: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
- Risk factors for return to work in workers who experienced cancer: a systematic review with meta-analysis.Oncology reviews · 2026Pooled it
- Cerium molybdate-doped polyaniline nanoplatform for GSH-depletion-enhanced chemodynamic/NIR-II photothermal synergistic therapy via ferroptosis and immune activation.Bioactive materials · 2027Article
- Dyadic relationship experience in Chinese patients with advanced cancer and their spouses: A longitudinal qualitative study.Asia-Pacific journal of oncology nursing · 2026Article
- Screening of peptide inhibitors targeting YAP-TEAD4 interaction: affinity evaluation and anti-AML cell activity.Journal of enzyme inhibition and medicinal chemistry · 2026Article
- Intratumoral therapeutic dust for chemo-photodynamic combination treatment.Science advances · 2026Article
- Convolvulus althaeoides as a Potential Natural Source in Cancer Prophylaxis and Treatment: LC-ESI-MS/MS, GC-MS, In Vitro, and In Silico Investigations.Chemistry & biodiversity · 2026Article
- Preparation and Characterization of Ocimum basilicum Extract-Loaded Niosomes and Evaluation of Their Cytotoxic and Pro-Apoptotic Potential in SKOV3 Ovarian Cancer Cells.Chemistry & biodiversity · 2026Article
- NF-κB-driven immune checkpoint knockdown and cytokine expression in cancer cells for tumor immunotherapy.iScience · 2026Article
- The Impact of Cancer Treatment On Oral Structures and the Facial Part of the Skull - Implications for Prosthetic Treatment and Oncological Risk.Current oncology reports · 2026Review
- Targeting of tripartite neuron-cancer-immune cell crosstalk augments response to chemotherapy and immunotherapy.Cell reports. Medicine · 2026Article
- The Relationship Between Immunogenic Cell Death and Cellular Senescence in Cancer Immunotherapy.Life (Basel, Switzerland) · 2026Review
- 4D nanoimaging-guided smart therapeutics: spatiotemporal control of disease microenvironments.RSC advances · 2026Review
- Novel Phenanthraquinone Derivative from Antarctic LichenACS omega · 2026Article
- Review
- Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer.Molecular oncology · 2026Review
- Amanitin-Based Fc-Small Molecule-Drug Conjugates with Noncleavable Linker: A Novel Therapeutic Strategy for Prostate Cancer Targeted Therapy.Molecular cancer therapeutics · 2026Article
- One-pot synthesis of Mn/Fe bimetal-doped metal-organic framework as multifunctional nanocarriers for esophageal cancer targeted therapy.Journal of pharmaceutical analysis · 2026Article
- Tuning epigenetics to enhance cancer virotherapy.Acta pharmaceutica Sinica. B · 2026Review
- Dual-Switchable Nanoparticles Resolving the Safety-Efficacy Paradox of Sonodynamic Immunotherapy for Hepatocellular Carcinoma.Advanced healthcare materials · 2026Article
452 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditional therapeutic approaches such as chemotherapy and radiation therapy have burdened cancer patients with onerous physical and psychological challenges. Encouragingly, the landscape of tumor treatment has undergone a comprehensive and remarkable transformation. Emerging as fervently pursued modalities are small molecule targeted agents, antibody-drug conjugates (ADCs), cell-based therapies, and gene therapy. These cutting-edge treatment modalities not only afford personalized and precise tumor targeting, but also provide patients with enhanced therapeutic comfort and the potential to impede disease progression. Nonetheless, it is acknowledged that these therapeutic strategies still harbour untapped potential for further advancement. Gaining a comprehensive understanding of the merits and limitations of these treatment modalities holds the promise of offering novel perspectives for clinical practice and foundational research endeavours. In this review, we discussed the different treatment modalities, including small molecule targeted drugs, peptide drugs, antibody drugs, cell therapy, and gene therapy. It will provide a detailed explanation of each method, addressing their status of development, clinical challenges, and potential solutions. The aim is to assist clinicians and researchers in gaining a deeper understanding of these diverse treatment options, enabling them to carry out effective treatment and advance their research more efficiently.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.